Publications

MB-101 (IL13Rα2-specific CAR)

2016 Abstract Presentations

Aguilar, B. et al. Optimization of IL13Rα2-specific CAR T cells for Clinical Development Using Orthotopic Human Glioblastoma Models in NSG Mice. 2016 American Society of Gene and Cell Therapy 19th Annual Meeting, May 4-7, 2016. Abstract #275.

Alizadeh, D. et al. Development of Murine IL13Rα2-Targeted CAR T Cells (mIL13BBz) for Assessment of CAR T Cell Therapy in Syngeneic Glioma Models. 21st Annual Meeting and Education Day of the Society for Neuro-Oncology, November 18, 2016. Abstract IMST-36.

Brown, C. et al. Phase I Study of Chimeric Antigen Receptor-Engineered T Cells Targeting IL13Ra2 for the Treatment of Glioblastoma. 21st Annual Meeting and Education Day of the Society for Neuro-Oncology, November 18, 2016. Abstract ATIM-13.

Brown, C. et al. Phase I Study of Second Generation Chimeric Antigen Receptor–Engineered T cells Targeting IL13Rα2 for the Treatment of Glioblastoma.  2016 American Society of Gene and Cell Therapy 19th Annual Meeting, May 4-7, 2016. Abstract #247.

Reference Articles

Brown, C. et al. Regression of Gliobastoma after Chimeric Antigen Receptor T-Cell Therapy. New England Journal of Medicine December 2016; 375: 2561-2569.

Jonnalagadda M, et al. Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy. Mol Ther. 2015;23: 757–768.

MB-102 (CD123 CAR)

2017 Abstracts

Budde, L., et al. Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial. 2017; Abstract #811.

Reference Articles

Mardiros A, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 2013;122: 3138–3148.

Wang X, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 2011;118(5): 1255-1263.